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Abstract 
 
Predictive toxicology aims at developing methodologies to relate the results obtained 
from in vitro experiments to in vivo exposure. In the case of polycyclic aromatic hydrocarbons 
(PAH), a substantial amount of knowledge on effects and modes of action has been recently 
obtained from in vitro studies of gene expression. In the current study, we built a 
physiologically based toxicokinetic (PBTK) model to relate in vivo and in vitro gene 
expression in case of exposure to benzo(a)pyrene (BaP), a referent PAH. This model was 
calibrated with two toxicokinetic datasets obtained on rats exposed either through 
intratracheal instillation or through intravenous administration and on an in vitro degradation 
study. A good agreement was obtained between the model’s predictions and the 
concentrations measured in target organs, such as liver and lungs. Our model was able to 
relate correctly the gene expression for two genes targeted by PAHs, measured in vitro on 
primary human macrophages and in vivo in rat macrophages after exposure to BaP. 
Combining in vitro studies and PBTK modeling is promising for PAH risk assessment, 
especially for mixtures which are more efficiently studied in vitro than in vivo.  
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1. Introduction 
 
Polycyclic aromatic hydrocarbons (PAHs) exert a variety of toxic responses toward 
human health, including carcinogenic, immunotoxic, neurodevelopmental and cardiovascular 
effects, and are likely to contribute to smoking-related diseases (Sorensen et al., 2003 ; 
Slotkin and Seidler, 2009). PAHs are products of incomplete combustion of fossil fuels, 
wood, and other organic materials at temperatures between 300 and 600 °C, and, as such, are 
ubiquitous in the environment. Benzo(a)pyrene (BaP), a five ring PAH, is usually used as a 
marker of exposure and effects of complex mixtures including PAHs, either directly (as a 
surrogate for the PAH fraction of complex mixtures) or using toxicity equivalency factors to 
relate the toxicity of each PAH to the one of BaP (Pufulete et al., 2004). In particular, BaP is 
the reference compound for lung cancer risk assessment relative to exposure to environmental 
PAHs (Vyskocil et al., 2004).  
A substantial amount of the knowledge on BaP mode of action and effects has been 
obtained in vitro. Human hazard assessment for regulatory purposes is still mainly carried out 
using animal studies, and seldom accounts for ongoing innovations in the field of in vitro 
toxicology. However, obtaining relevant dose-response relationships for systemic endpoints, 
like reproductive toxicity or cancer, based on extrapolated in vitro data, is a great challenge to 
avoid expensive and lengthy in vivo testing. It is envisioned by toxicologists that future risk 
assessment would focus on avoiding significant perturbations in toxicity pathways through in 
vitro toxicity pathway assays on human cells or cell lines (Krewski et al., 2010). To integrate 
the in vitro results into quantitative in vivo risk assessment, these assays would be analyzed 
with computational systems biology models to derive an in vitro dose-response, which would 
then be extrapolated in vivo based on toxicokinetic of the chemicals in the organism of 
interest. For instance, Verwei et al. (2006) showed that the combination of in vitro tests for 
embryotoxicity with toxicokinetic modeling permits relevant predictions of in vivo 
developmental effects in rodents. Although combining in vitro and in silico techniques 
appears as a promising alternative test method for risk assessment, such methodology is still 
rarely applied.  
Macrophages are target cell types for PAHs, with consequences related to immune 
response, inflammatory pathways, tissue injuries, atherosclerosis, monocyte differentiation 
and lipid accumulation. In order to identify early markers of toxicity that may potentially be 
linked with the occurrence of pathologies, the expression of the genes of macrophages has 
been studied after exposures to different doses of BaP. Expression of many genes, including 
interleukin (IL)-1β, IL-8, tumor necrosis factor (TNF)-α, NADPH oxidase subunit gene 
neutrophil cytosolic factor 1 (NCF1), and CC-chemokine ligand 1, was found up-regulated in 
human blood monocyte-derived macrophages or rodent alveolar macrophages (Lecureur et 
al., 2005 ; N’Diaye et al., 2006 ; Podechard et al., 2008 ; Pinel-Marie et al., 2009). The nature 
of molecular BaP target genes in primary human macrophages has recently been 
characterized (Sparfel et al., 2010). IL-1β and the aryl hydrocarbon receptor (AhR) repressor 
were confirmed as targets, whereas new targets were found, including the chemokine receptor 
CXCR5, the G protein coupled receptor 35 (GPR35), and the Ras regulator RASAL1.  
Physiologically based toxicokinetic (PBTK) models are particularly relevant to relate in 
vitro and in vivo responses, since the modeling of the toxicokinetic of chemicals is based on 
the physiology of the organism and that the internal dosimetry in the target tissues may be 
assessed. Few PBTK models for BaP have been already developed in rats (Roth and Vinegar, 
1990 ; Zeilmaker et al., 1999 ; Moir, 1999). These models suffer from different problems 
which make questionable their use in lung toxicity assessment. All of these models were 
developed with toxicokinetic data of BaP in different organs/tissues after an intravenous 
administration. Even if these data described the distribution of BaP into the tissues from blood 
circulation, they were unable to inform the absorption of BaP through the lungs, which is the 
major route of exposure of PAHs. The kinetics of BaP in lungs was also not well reproduced 
by these models. Either lungs were not described by the model (Zeilmaker et al., 1999) or the 
partition coefficient between lungs and blood, estimated through QSAR modeling (Chiang 
and Liao, 2006), equilibrium dialysis experiment (Moir, 1999) or interactive adjustment (Roth 
and Vinegar, 1990), was low compared to actual concentration data in lungs and blood 
(Schlede et al., 1970 ; Weyand and Bevan, 1986). These models would consequently 
underestimate BaP lung concentration. There is therefore a need to improve the modeling of 
the lungs toxicokinetics.  
In this paper, we propose to combine the toxicokinetic modeling of BaP in vivo and dose-
response relationships derived in vitro to assess the effects of BaP on the expression of two 
target genes for PAHS, IL-1β and NCF1. First experimental in vitro assays on macrophages 
will be conducted to construct dose-response models for the expression of the two genes. 
Then a PBPK model for BaP in rats including the description of lungs will be calibrated with 
concentrations in different tissues after an intratracheal instillation (Weyand and Bevan, 1986) 
and an intravenous administration (Schlede et al., 1970). Intratracheal instillation is a useful 
and cost-effective procedure for addressing specific questions regarding the respiratory 
toxicity of chemicals and presents many advantages over inhalation (Driscoll et al., 2000): the 
actual dose delivered to the lungs can be assured, a range of doses can be introduced into the 
lungs within a short time, and exposure to the skin and pelt can be avoided. Once 
parameterized, the PBPK model will be linked to the dose-response relationships derived in 
vitro to extrapolate the in vitro responses to in vivo conditions. The prediction of the 
expression of the genes will then be compared to actual responses obtained from an exposure 
of rat to BaP. Our methodology is illustrated in Figure 1.  
 
2. Materials and methods 
 
2.1.Toxicokinetics data in rats for BaP and metabolites 
 
Two sets of toxicokinetic data were used. The first one, by Weyand and Bevan (1986), 
was obtained in Sprague-Dawley rats after an intratracheal instillation of 1 µg/kg BaP. It has 
never been used for PBTK modeling. Concentrations of BaP and metabolites were measured 
in lungs, liver, blood and intestine at different times from 5 to 360 min after instillation. 
Animals were maintained on a steep incline for 5-10 min following BaP administration. It 
was not clear if this period was accounted for in calculating the time between administration 
and measurement. We consequently did not use the data at 5 and 10 min for the estimation of 
parameters to avoid the use of confounding measurements. These data are however presented 
in the figures from the result section.  
We analyzed Weyand and Bevan dataset together with other existing and available data 
obtained in Sprague-Dawley rats after an intravenous administration of 10 µg BaP (Schlede et 
al., 1970). These data have previously been used in a PBTK modeling context, to compare 
with the outputs of a model in development (Roth and Vinegar, 1990). These data comprise 
lungs, liver, adipose tissues and blood BaP concentrations at different times from 5 to 360 
min. In addition to contributing to build a model robust enough to account for different 
exposure routes, the use of this second dataset was necessary to account for the kinetics in 
adipose tissues. These tissues store and release a substantial quantity of BaP with an 
important influence on long-term kinetics.  
 
2.2.In vitro exposure of macrophages to BaP  
 
Peripheral blood mononuclear cells were obtained from blood donor buffy coats (kindly 
provided by the Etablissement Français du Sang, Rennes, France), through Ficoll (Life 
Technologies, Cergy-Pontoise, France) gradient centrifugation. After a selective 2-h step of 
adhesion, human adherent monocytes were cultured for 6 days in RPMI 1640 medium 
(Eurobio, Les Ulis, France), supplemented with 2 mM L-glutamine, 20 units/ml penicillin, 20 
µg/ml streptomycin and 10 % decomplemented fetal bovine serum (Thermo Fischer 
Scientific, Perbio Science, Berbières, France), in the presence of 400 units/ml granulocyte 
macrophage-colony stimulating factor (Schering Plough, Lyon, France). Such a protocol 
permits to obtain pure macrophagic cultures, validated by analysis of the expression of the 
macrophagic marker CD71, with less than 1% of contaminating cells such as CD3- or CD19-
positive lymphocytes, as assessed by immunophenotyping (van Grevenynghe et al. 2004). 
Macrophagic cells were cultured in serum-free medium for 24 h prior to a 24-h exposure to 
various increasing BaP concentrations (0-10 µM). 
 
2.3.Exposure of rats to BaP 
 
Male Sprague-Dawley rats were purchased from Charles River Laboratory (L'Abresle, 
France). They were maintained under standardized conditions (relative humidity 55±15%, 12-
h day night cycle, room temperature 22±2°C). Rats were exposed to 3 mg/kg BaP dissolved 
in NaCl-bovine serum albumin by intratracheal instillation. Control rats received vehicle only. 
Twenty four hours after the instillation, animals were euthanized with a lethal dose of sodium 
pentobarbital (Ceva Santé Animale, France). After exsanguinations, bronchoalveolar lavages 
were performed and alveolar macrophages were collected. We did not observe alterations of 
the percentage of alveolar macrophages in bronchoalveolar lavages due to BaP treatment 
(data not shown). The experimental protocol has been approved by the local ethical 
committee for animal research. 
 
2.4.RNA isolation and reverse transcription–real time quantitative PCR assay (RT-qPCR) 
 
Total RNA was isolated from macrophages using the TRIzol method (Invitrogen, Cergy-
Pontoise, France). Total RNA (1 µg) was reverse-transcribed into cDNA using the RT 
Applied Biosystems kit (Foster City, CA). Quantitative PCR (qPCR) assays were next 
performed using the fluorescent dye SYBR Green methodology and an ABI Prism 7000 
detector (Applied Biosystems). The gene specific primers were provided by Qiagen 
(Courtaboeuf, France). The specificity of each gene amplification was verified at the end of 
qPCR reactions through analysis of dissociation curves of the PCR products. Amplification 
curves were analysed with ABI Prism 7000 SDS software using the comparative cycle 
threshold method. Relative quantification of the steady-state target mRNA levels was 
calculated after normalization of the total amount of cDNA tested to a 18S mRNA 
endogenous reference.  
  
2.5.In vitro dose response modeling 
 
The Hill model was used to fit the dose-gene expression profile, as it has already been 
proposed by other authors (Varma et al., 2007). The Hill function we used has the general 
form: 
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where the baseline activity is 1 with no BaP, Emax is the maximum gene expression level, c50 
is the dose resulting in 50% of the maximum increase in gene expression, n is the Hill 
coefficient defining the shape of the dose–response curve and c is the BaP concentration.  The 
model was fitted to the experimental in vitro gene expression using the least squares method 
with a prior normalization for each concentration by the standard error of the response to 
avoid overweighting high concentrations. Confidence intervals were calculated through data 
bootstrapping. The software R, version 2.7.1, was used (R Development Core Team, 2008). 
 
2.6.PBTK modeling  
 
Figure 2 presents a description of the PBTK model. The body is represented by lungs, fat, 
liver, richly perfused and slowly perfused tissues. The model is divided into two sub-models, 
one for BaP, and one for its metabolites, treated as a whole by assuming common kinetics for 
simplification. The sub-models are connected through liver metabolism. To describe BaP 
kinetics, fat is separated between adipose tissues and blood in adipose tissues to account for 
diffusion in this compartment (Zeilmaker et al., 1999 ; Moir, 1999).  
For metabolites, we assumed that adipose tissues, richly and slowly perfused tissues had 
the same partition coefficient with blood and that there was no diffusion limitation in adipose 
tissues. We assumed that only metabolites (and no parent compound) were found in the 
intestine as suggested by Weyand and Bevan, who found that less than 2% of intestinal 
content was BaP after 60 and 360 min.  
The parameters of the model are presented in Table 1. The differential Equations 1–5 were 
used to calculate the change in amount of BaP and metabolites over time in the PBTK model 
compartments. 
In general, kinetics in organ i is described by the equation: 
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with Ci, Vi Qi and Pi respectively the concentration, the volume, the blood flow and the 
partition coefficient with blood of organ i, and cb the concentration in blood (venous for lung, 
arterial for the other organs).  
For adipose tissues, the kinetics of BaP in blood and in tissues is described by: 
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For liver, the kinetics of BaP is described by: 
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and the kinetics of metabolites by: 
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2.7.Calibration of the PBTK model 
 
The parameters we estimated were the partition coefficients between blood and lung, 
liver, and slowly perfused tissues for BaP, the partition coefficients between blood and lung, 
liver, and other tissues for metabolites, and the metabolite elimination rate. Parameters were 
estimated through maximum likelihood methods. We fitted simultaneously the two datasets 
with common parameters, with the exception of liver partition coefficient which had to be 
differentiated to fit liver concentration data in both studies. The measurement errors were 
assumed to be independent and log-normally distributed, with a geometric mean equal to the 
PBTK model predictions and a geometric standard deviation (GSD) of 1.1 (approximately 
10% error) for BaP, and 1.2 for metabolites. We chose a higher GSD for metabolites 
compared to parent compound because the concentrations were calculated as the difference 
between two measured concentrations (total concentration minus BaP concentration). Data 
likelihoods were therefore given by: 
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where the function F(X,θ) corresponds to a PBTK model with input X and parameters θ, and 
σc is equal to either 1.1 or 1.2. Parameters estimation and building of confidence intervals 
were performed using the MCSim software (Bois and Maszle, 1997).  
 
3. Results 
 
3.1.PBTK modeling 
 
The fits of the PBTK model to Weyand and Bevan (1986) data are presented in Figure 3 
for blood, lung, liver and intestines. The fits of the model to the Shlede et al. (1970) data are 
presented in Figure 4 for blood, lung, liver and adipose tissues. Only 2 out of the 52 
predictions differ from the measured values by a factor higher than 2. Parameters’ estimates 
are given in Table 1. Confidence curves relative to the estimated parameters are shown in 
Figures 3 and 4. 
The same parameters were used for both studies, with the exception of liver partition 
which was more than 5 times higher for Weyand and Bevan data compared to Shlede data. 
We found high partition coefficient values for liver and lung, when compared to the values 
usually used in risk assessment based on QSAR modeling (Chiang and Liao, 2006). In 
contrast, coefficients for slowly perfused tissues were within expected ranges based on QSAR 
or dialysis experiments (Chiang and Liao, 2006 ; Moir, 1999) and predicted hepatic clearance 
was well accounted for based on the in vitro study by Wiersma and Roth (1983). For all 
tissues, metabolites had lower partition coefficients than BaP.   
 
3.2.In vitro dose-response model for the Gene expression 
 
Figure 5 presents the results of IL-1β and NCF1 mRNA induction in response to various 
increasing concentrations of BaP in primary human macrophages. IL-1β and NCF1 inductions 
were significantly greater than 1 for respectively concentrations over 0.12 and 0.04 µM 
(multirange Dunnett's t test, p<0.05). The fit with the Hill model provided the following 
estimates for IL-1β with 95% confidence intervals: n=1.4 [1.16; 1.86], Emax=126 [42; 166], 
c50=5.6 [2.7; 9.3]. We obtained the following estimates for NCF1 with 95% confidence 
intervals: n=0.65 [0.55; 0.9], Emax=25 [15; 27], c50=13 [5; 18].  
 
3.3.Prediction of in vivo gene expression based on TK/TD modeling 
 
 
The PBTK model was used to predict the toxicokinetic profile of BaP in lungs during 24h 
after an intratracheal instillation of 3 mg/kg. Since two different values were estimated for the 
partition coefficient liver:blood from the two toxicokinetic datasets, both estimates were used 
to run the model. No significant difference was observed on the predicted lungs 
concentrations. Figure 6 presents the predicted internal dosimetry in lungs for 24 hours. Since 
only little information was available to determine the entity responsible of the modulation of 
the gene expression, three model outputs were chosen: the concentration in lungs at the time 
of the appearance of the effect and the mean concentration in lungs during the last hour or the 
last four hours before the appearance of the effect. The time ranges of one or four hours 
before the appearance of the effect are supported by previous results. Pinel-Marie et al. (2009) 
showed that 1 to 4 hours are necessary to induce a change in the gene expression after an in 
vitro exposure of macrophages to 2 µM of BaP. Table 2 presents the internal concentrations in 
lungs with the respective prediction of the gene expressions obtained with the dose-response 
model. We observed that these predicted gene expressions are quite similar for the 3 
concentrations in lungs (3.3 to 3.6-fold for NCF1, and 3.8 to 4.9-fold for IL-1β).  
These predictions were compared to the values observed in the in vivo studies in rats. In 
vivo, a mean induction of 2.39-fold for NCF1 and 3.72-fold for IL-1β was observed in 
alveolar macrophages from rats treated by intratracheal instillation of BaP when compared to 
alveolar macrophages from untreated rats. For the gene IL-1β, a good concordance is obtained 
between the predictions of the PBTK model linked to the dose-response model derived with 
in vitro data and the actual values measured in rats. For the gene NCF1, the modelling 
approach tends to over-predict slightly the gene induction. The dose-response model was used 
in reverse to estimate the concentration in lungs that would provide the observed in vivo 
inductions. A concentration of 0.36 µM was predicted for IL-1β and 0.17 µM for NCF1.  
 
4. Discussion  
 
4.1.PBTK modeling 
 
We could calibrate a PBTK model based on intratracheal instillation and intravenous 
administration, with a quality of fit which has not been reached by previous attempts to build 
a PBTK model for BaP.  
Contrary to Moir (1999), we were able to describe the data with our model using the 
metabolic parameters estimated in vitro (Wiersma and Roth, 1983). Usually, it is accepted 
that Km values does not change between in vitro and in vivo situations, but that Vmax value has 
to be adjusted (Haddad et al., 1998). As in the model by Roth and Vinegar (1990), such an 
adjustment was not necessary. Metabolism in the lungs is likely to occur, but was neglected in 
our model. We showed that the introduction of pulmonary clearance, with parameters from 
Wiersma and Roth (1983), would not have affected our results (less than 5% difference in the 
predictions for lung concentration). Previous results with intravenous administration confirm 
this poor influence of lung metabolism. Intravenous administration and intratracheal 
instillation lead to close kinetics, as shown by Weyand and Bevan (1986) because of the high 
rate of exchange between blood and lungs. In their study of intravenous administration of 29.5 
µg/kg BaP, which is close to the doses used in the studies we analyzed, Roth and Vinegar 
(1990) showed that the amount of BaP metabolized by the lung compared to the total amount 
of metabolized BaP is only 3.5%. In their study, lung metabolism was substantial only when 
animals had been pretreated with cytochrome P450 monooxygenase inducer 3-
methylcholanthrene in agreement with previous studies (Seifried, 1977).  
We estimated partition coefficients values between blood and lung which are far above 
those previously used for PAH risk assessment. Metabolizing tissues contain macromolecules, 
like AhR and other proteins, to which PAH compounds may specifically bind (Haddad et al., 
1998). Consequently, the algorithm by Poulin and Krishnan (1995) used by Chiang and Liao 
(2006), which is based on the neutral lipid, phospholipid and water contents of blood and 
organs, may not be appropriate to estimate PAH partition coefficients for lung and liver.   
Liver partition estimate was more than 5 times higher for Weyand and Bevan data, 
corresponding to the study with the lowest exposure dose, compared to Shlede data. This 
difference could be due to a sequestration mechanism (AhR) at low concentrations which is 
saturated for higher concentrations or it could be due to differences in BaP measurement 
methods in liver between the two studies. This difference is just related to liver concentration, 
but did not affect hepatic clearance which remained the same for the two studies, as liver 
concentrations were far below Michaelis metabolism constant in the liver.   
We integrated BaP metabolites in our model, but did not distinguish between the different 
compounds. Weyand and Bevan showed that the repartition between the metabolites in lung, 
liver and intestine was relatively constant from 60 to 360 min, and we consequently believe 
that the modeling of the kinetics of BaP metabolites using common parameters is still 
realistic.  
 
4.2.Gene expression data 
 
We used our model to predict lung concentration after intratracheal instillation for a dose 
of 3 mg/kg BaP and obtained a good correlation between gene expression responses in human 
macrophages in vitro exposed to BaP and in rat counterparts in vivo exposed to the PAHs. 
This suggests that human and rat macrophages in different tissues provide comparable 
response to BaP exposure, at least relative to mRNA induction, and that our PBTK model is 
able to link in vitro and in vivo responses through the calculation of macrophage exposure in 
rat.  
We related gene expression either to the concentration at a given time or to the mean of 
concentration during the last one or four hours. There was little difference relative to the 
prediction in vivo even if the one related directly to the mean concentration at a given time 
provided the closest prediction compared to actual values. It is important to note that the mean 
value or the concentration value is not necessarily the right endpoint when relating in vitro 
and in vivo toxicity. For instance, Verwei et al. (2006) referred to the maximum internal 
concentration when succeeding to relate developmental effects assessed in vitro and in vivo 
assuming that such effects occur as soon as a threshold is exceeded. In our study, we tried 
alternatives such as mean lung concentration over the whole exposure interval or highest lung 
concentration, but the resulting predictions for genes expression would have largely exceeded 
the measurements.  
Our results are promising for we have developed a predictive tool able to transpose at a 
systemic level dose-response obtained quickly on cells. In particular, assessing the response 
of cells exposed to complex mixtures including PAH compounds would be much easier in 
vitro than in vivo.  
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Table 1 
Parameters of the PBTK model for Sprague Dawley rats (0.25 kg) exposed to BaP. Blood 
flows were calculated based on cardiac output in Davies and Morris (1993) and percentages 
of cardiac output in Haddad et al. (1998). Partition coefficient for richly perfused tissues was 
taken from measurements by Moir (1999). Partition coefficient for adipose tissues was taken 
as the mean experimental measurement by Zeilmaker et al. (1999). Michaelis constant and 
maximum metabolism rate for liver came from an in vitro study (Wiersma and Roth, 1983) 
and were extrapolated to rats by using the allometric scaling for interspecies extrapolation 
(Haddad et al., 1998). Diffusion coefficient in adipose tissues was assumed to be the same 
value as used by Haddad et al. (1998) for pyrene.  
 
Volume of venous blood  Vvb 10 mL Haddad et al, 1998 
Volume of arterial blood Vab 5 mL Haddad et al., 1998 
Volume of fat Vf 22.5 mL Haddad et al, 1998 
Volume of blood in fat Vbf 0.15 mL Haddad et al, 1998 
Volume of slowly perfused tissues Vs 167.5 mL Haddad et al., 1998 
Volume of richly perfused tissues Vr 9.5 mL Haddad et al, 1998 
Volume of lung Vl 3mL Haddad et al, 1998 
Volume of liver Vh 10 mL Haddad et al, 1998 
Adipose blood flow Qf 6.7 mL/min Haddad et al, 1998 
Slowly perfused blood flow Qs 11.1 mL/min Haddad et al, 1998 
Richly perfused blood flow Qr 37.8 mL/min Haddad et al, 1998 
Total blood flow (Cardiac output) Qc 74 mL/min Davies and Morris, 1993 
Liver blood flow Qh 18.4 mL/min Haddad et al, 1998 
BaP PC fat over blood Pf 50 Zeilmaker et al., 1999 
BaP PC slowly perfused tissues over blood Ps 3.5 Estimated 
BaP PC richly perfused tissues over blood Pr 1.6 Moir, 1999 
BaP PC lung over blood Pl 88 Estimated 
BaP PC liver over blood Ph 134 
 
25 
Estimated from Weyand 
and Bevan data 
Estimated from Schlede 
et al data. 
Metabolites PC lung over blood PMl 25.7 Estimated 
Metabolites PC liver over blood PMh 7.9 Estimated 
Metabolites PC other tissues over blood PMo 1.7 Estimated 
Metabolites elimination rate  Kelim 0.321 mL/min Estimated 
Liver maximum metabolism rate Vmax 0.087 mg/min Wiersma and Roth, 1983 
Liver metabolism Michaelis constant Km 0.00139 mg/mL Wiersma and Roth, 1983 
Diffusion coefficient in adipose tissues D 1.7 mL/min Haddad et al, 1998 
 
Table 2 
Predicted mean value and confidence interval (between brackets) for BaP lung concentration 
for a selected period of time and corresponding IL-1β and NCF1 inductions. The actual 
induction value is also provided.  
 
 Lung concentration (µM) IL-1β  induction NCF1 induction 
Concentration  at 24h 
 
0.37 [0.34;0.4] 3.3 [3.2;3.4] 3.8 [3.6;4.3] 
Mean concentration 
between 23h and 24h 
0.42 [0.39;0.45] 3.4 [3.3;3.5] 4.3 [4.2;5] 
Mean concentration 
between 20h and 24h 
0.47 [0.43;0.51] 3.6 [3.4;3.7] 4.9 [4.7;5.7] 
Measured value  2.4 3.7 
 
  
 Figure legends 
 
Fig. 1. Schematic presentation of the methodology used to compare predicted and actual gene 
expression in rodents exposed to BaP.  
 
Fig. 2. Schematic presentation of the PBTK model used to describe the kinetics of BaP and its 
metabolites. Symbols are presented in Table 1. 
 
Fig. 3.  BaP and metabolites kinetics in blood, lung , liver and intestine (data points are mean 
values from Weyand and Bevan, and fits with 95% confidence intervals). 
 
Fig. 4. BaP kinetics in blood, lung, liver and fat (data points are mean values from Schlede et 
al., and fits with 95% confidence intervals). 
 
Fig. 5. IL-1β and NCF1 mRNA induction in response to BaP treatment in primary human 
macrophages. Data are expressed relative to mRNA levels found in untreated cells, arbitrarily 
set at a value of 1. The fit with the Hill model is presented.  
 
Fig. 6. Time course of lung BaP concentration in rats after intratracheal instillation of 3 
mg/kg, as predicted by the PBTK model.   
 
 
